Moreover, given that “on-target/off-tumor” toxicities of current CD19- and BCMA-CAR-T products, such as hypogammaglobulinemia following B-cell depletion, are well described and manageable [1, 9], it seems unlikely that combinatorial targeting of these antigens will result in any unanticipated off-tumor side effects. The gene discussed is TNFRSF17; the disease is neoplasm.